The Why? Series

Why do we need TPE in liver disease? Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are associated with high mortality unless treated appropriately .1 Therapeutic plasma exchange...

Autoimmune hepatitis (AIH) is a relatively rare chronic, autoimmune disorder of the liver with rising prevalence in the United States and globally. Since its identification in the mid-twentieth...

Background, Pathophysiology and Epidemiology Portomesenteric venous thrombosis (PMVT) is a frequently-observed finding in patients with cirrhosis. The most common type of PMVT is portal vein...

Frailty is a prevalent complication of end-stage liver disease and is characterized by decreased physiologic reserve and increased vulnerability to health stressors. The concept of frailty matters in...

Ascites is a common complication of cirrhosis secondary to hemodynamic changes that cause systemic and splenic vasodilation as result of increased nitric oxide. The presence of ascites is associated...

Introduction Primary sclerosing cholangitis (PSC) is a heterogenous and progressive disease of the biliary tree, resulting in fibrosis and the eventual development of cirrhosis. Due to recurrent...

Viral hepatitis has been and remains a formidable global health challenge. To effectively combat this, we employ a powerful tool: vaccinations. In this discussion, we will delve into the intricacies...

Hepatic encephalopathy (HE) is one of the major reasons patients with cirrhosis are admitted to the hospital. Often before they have been seen by the gastroenterology or hepatology team, a serum...

Why is it important to think about non-cirrhotic portal hypertension? Let’s start with a case! A 25 yo with history of Common Variable Immunodeficiency (CVID) on monthly IVIG presents to the emergency...